BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/02/2024
|
BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
- BOTHELL, Wash., April 30, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024.
- 04/30/2024
|
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business
- BOTHELL, Wash. , April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").
- 04/18/2024
|
BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences
- BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef, Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March Investor Conferences.
- 03/04/2024
|
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
- BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
- 02/29/2024
|
BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results
- Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million, and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and positive adjusted EBITDA Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.
- 02/29/2024
|
BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024
- BOTHELL, Wash. , Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024.
- 02/20/2024
|
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
- Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash. , Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.
- 01/08/2024
|
BioLife Solutions: A Complicated Tale
- BioLife Solutions, Inc. is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. The company offers bioproduction tools and services for the cell and gene therapy industry, with recurring revenue streams making up about 65% of its revenue. The cell and gene therapy market is expected to continue growing, but BioLife's recent financial performance and management changes have caused concern.
- 11/29/2023
|
BioLife Solutions, Inc. (BLFS) Q3 2023 Earnings Call Transcript
- BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Rod de Greef - Chairman and CEO Conference Call Participants Jacob Johnson - Stephen Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Steven Mah - TD Cowen Thomas Flaten - Lake Street Michael Okunewitch - Maxim Group Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst Conference Call.
- 11/09/2023
|
BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023
- BOTHELL, Wash. , Nov. 2, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023.
- 11/02/2023
|
BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023
- Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of $33.3 million and expect 2023 revenue at the low end of the previously announced guidance range BOTHELL, Wash. , Oct. 19, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced Roderick de Greef has been appointed as Chairman of the Board of Directors and Chief Executive Officer replacing Michael Rice who is retiring after a seventeen year tenure, effective immediately.
- 10/19/2023
|
New Strong Sell Stocks for October 9th
- BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.
- 10/09/2023
|
New Strong Sell Stocks for September 13th
- BLFS, ALCO and AFCG have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2023.
- 09/13/2023
|
BioLife Hit By An Inventory Correction
- BioLife is facing setbacks due to a difficult funding environment, inventory corrections, and a decline in COVID-related revenues. The company's acquisitions have negatively impacted margins and cash flow. Management plans to divest the freezer business, which is expected to improve financials and the balance sheet and will provide an impetus for the stock.
- 08/30/2023
|
Why Shares of BioLife Solutions Plummeted This Week
- BioLife Solutions focuses on cell- and gene-therapy preservation tools, used primarily by the biotech industry. The company did trim its losses, year over year, in the quarter.
- 08/11/2023
|
Why Shares of BioLife Solutions Are Slumping on Wednesday
- BioLife Solutions said it is divesting itself of some assets to focus on its higher-margin business. The company saw declining revenue but narrowed its losses dramatically.
- 08/09/2023
|
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates
- BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago.
- 08/08/2023
|
Atrion Corp (ATRI): A Medical Device Stock with Good Outperformance Potential
- Atrion Corp ( ATRI , Financial), a leading player in the Medical Devices & Instruments industry, is currently trading at $557 per share. The company has a market capitalization of $980.596 million and has seen a stock price gain of 4.7% today.
- 08/08/2023
|
EVP & Chief Scientific Officer Aby Mathew Sells 20,000 Shares of BioLife Solutions Inc (BLFS)
- On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 shares of the company's stock. This recent transaction is part of a series of insider sales by Mathew over the past year, totaling 111,135 shares sold and no shares purchased.
- 05/27/2023
|
EVP & Chief Scientific Officer Aby Mathew Sells 20,000 Shares of BioLife Solutions Inc
- On May 25, 2023, Aby Mathew, the Executive Vice President and Chief Scientific Officer of BioLife Solutions Inc ( BLFS , Financial), sold 20,000 shares of the company's stock. This recent transaction is part of a broader trend of insider selling at BioLife Solutions Inc, which we will analyze in this article.
- 05/26/2023
|
BioLife Solutions, Inc. (BLFS) Q1 2023 Earnings Call Transcript
- BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Troy Wichterman - CFO Michael Rice - Chairman & CEO Conference Call Participants Jacob Johnson - Stephens Inc. Thomas Flaten - Lake Street Capital Markets Chad Wiatrowski - TD Cowen Carl Byrnes - Northland Capital Markets Yuan Zhi - B. Riley Securities Paul Knight - KeyBanc Capital Markets Operator Hello.
- 05/10/2023
|
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates
- BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.
- 05/10/2023
|
BioLife Solutions: Capitalizing On The Future Of Biopreservation
- BioLife Solutions, a leading provider of bioproduction tools and services, is poised for growth as the demand for biologics and regenerative medicine increases. CryoStor and HypoThermosol have shown significant improvement to the post-preservation viability of biologic materials during manufacturing, storage, and distribution.
- 03/28/2023
|
BioLife Solutions Is Set To Finally Absorb Its Acquisitions
- An acquisition spree has produced a host of problems, costs, write-offs, a collapse in gross margins and profits, cash bleed, and significant dilution. While only the evo and Sexton acquisitions have been a real success, the problems at some of the others now seem to be largely in the rearview mirror.
- 03/25/2023
|
BioLife Solutions, Inc. (BLFS) Q4 2022 Earnings Call Transcript
- BioLife Solutions, Inc. (NASDAQ:BLFS ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Mike Rice – Chairman and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Yuan Zhi – B. Riley Thomas Flaten – Lake Street Operator Good day, and welcome to the BioLife Solutions' Fourth Quarter 2022 and Full Year Earnings Call.
- 03/16/2023
|
BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences
- BOTHELL, Wash. , Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced the dates of its 2023 analyst day and upcoming investor conferences where management will be presenting and meeting with current and prospective investors.
- 01/17/2023
|
BioLife Solutions: Inventory Movement A Key Benchmarking Factor, Retain Hold
- BioLife Solutions, Inc. guidance narrowed for full-year estimates, whilst there were several observable challenges exhibited in Q3 numbers. It could be a while before the company returns back to profitability, hence, the investment and valuation metrics don't stack up at present.
- 01/05/2023
|
BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023
- Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL, Wash.
- 12/19/2022
|
BioLife Solutions, Inc. (BLFS) Q3 2022 Earnings Call Transcript
- BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Mike Rice - Chairman & Chief Executive Officer Rod de Greef - President & Chief Operating Officer Conference Call Participants Paul Knight - KeyBanc Thomas Flaten - Lake Street Jacob Johnson - Stephens Stephanie Iannetta - Cowen and Company Yuan Zhi - B. Riley Securities Suraj Kalia - Oppenheimer Operator Good afternoon, ladies and gentlemen and thank you for standing by.
- 11/09/2022
|
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates
- BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2022
|
BioLife: What The Future Holds
- BioLife recently formed a strategic partnership with CSafe to expand its service repertoire for its customers. The latest quarter reported extremely strong growth across all operations.
- 10/19/2022
|
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q2 2022 Results - Earnings Call Transcript
- BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Mike Rice - Chairman and Chief Executive Officer Rod de Greef - President and Chief Operating Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Hannah Hefley - Stephens Max Masucci - Cowen and Company Suraj Kalia - Oppenheimer Operator Good day. My name is Chantel, and I'll be your conference operator today.
- 08/09/2022
|
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
- BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2022
|
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2022 Results - Earnings Call Transcript
- BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Troy Wichterman - Chief Financial officer Mike Rice - Chairman and Chief Executive Officer Rod De Greef - President and Chief Operating Officer Conference Call Participants Max Masucci - Cowen and Company Jacob Johnson - Stephens Inc. Thomas Flaten - Lake Street Capital Markets Suraj Kalia - Oppenheimer Operator Welcome to the BioLife Solutions First Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.
- 05/09/2022
|
New Strong Sell Stocks for May 2nd
- ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
- 05/02/2022
|
BioLife: Can This Company Successfully Turn Around?
- A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy.
- 04/18/2022
|
New Strong Sell Stocks for March 31st
- BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.
- 03/31/2022
|
Temporary Setbacks At BioLife
- One of its acquired companies, Sterling, could not cope with the rapidly rising demand and this generated substantial one-off costs, marring the figures.
- 03/02/2022
|
BioLife Solutions to Attend and Present at Upcoming Investor Conferences
- BOTHELL, Wash., March 1, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT) and the broader biopharma markets, today announced Mike Rice, Chairman and CEO, Rod de Greef, President and COO, and Troy Wichterman, CFO, are scheduled to present at both the Cowen and KeyBanc Investor Conferences in March 2022.
- 03/01/2022
|
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results - Earnings Call Transcript
- BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
- BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022
- BOTHELL, Wash., Feb. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2021 financial results will be released after market close on Monday, February 28 th.
- 02/21/2022
|
PETQ or BLFS: Which Is the Better Value Stock Right Now?
- PETQ vs. BLFS: Which Stock Is the Better Value Option?
- 02/11/2022
|
Best Biotech Stocks to Invest in Now
- Try your hand at morphing science and business for a great investment opportunity in biotech.
- 01/28/2022
|
BioLife: Poised For Growth
- BioLife Solution is enjoying robust growth years over years.
- 12/22/2021
|
BioLife Solutions, Inc. (BLFS) CEO Mike Rise on Q3 2021 Earnings Conference Call -Earnings Call Transcript
- BioLife Solutions, Inc. (BLFS) CEO Mike Rise on Q3 2021 Earnings Conference Call -Earnings Call Transcript
- 11/11/2021
|
BioLife Solutions to Report Third Quarter 2021 Financial Results and Provide Business Update on November 11, 2021
- BOTHELL, Wash., Nov. 4, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2021 financial results will be released after market close on Thursday, November 11 th.
- 11/04/2021
|
Analysts Estimate BioLife Solutions, Inc. (BLFS) to Report a Decline in Earnings: What to Look Out for
- BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/28/2021
|
Have $500? This Under-the-Radar Stock Could Make You Richer From the Biotech Boom
- This company is preserving biological material and can help your portfolio grow.
- 10/15/2021
|
Notable Biolife Solutions Insider Trades $971 Thousand In Company Stock
- Aby Mathew, Exec VP And Chief Scientific Off at Biolife Solutions (NASDAQ:BLFS), made a large buy and sell of company shares on September 22, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Aby Mathew exercised options to purchase 20,000 Biolife Solutions shares at a price of $1.64 per share for a total of $32,800 on September 22.
- 09/23/2021
|
Why Shares in BioLife Solutions Jumped 24.4% in August
- The company, which specializes in cold-storage solutions for biotechs, had a hot month.
- 09/07/2021
|
BioLife Solutions Files Form S-3 Registration Statement to Register Shares from Completed Acquisitions
- BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, announces that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission ("SEC") to register approximately 10.7 million shares of restricted common stock held by stockholders of previously acquired companies Global Cooling, Inc. (operating as Stirling Ultracold), SciSafe Holdings, Inc. and Sexton Biotechnologies, Inc., as well as certain shares held by Casdin Capital.
- 09/01/2021
|
BioLife Solutions Closes Acquisition of Sexton Biotechnologies
- BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies.
- 09/01/2021
|
BLFS Stock: 19.62% Increase Explanation
- The stock price of BioLife Solutions Inc (NASDAQ: BLFS) increased by 19.62% today. This is why it happened.
- 08/25/2021
|
2 Little-Known Nasdaq Stocks Making Big Moves Wednesday
- Don't let these companies fly under your radar.
- 08/25/2021
|
BioLife Solutions Joins S&P SmallCap 600 Index
- BOTHELL, Wash., Aug. 25, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that its common stock will be added to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021.
- 08/25/2021
|
BioLife Solutions: The Whole Is Much More Than The Sum Of The Parts
- BioLife Solutions: The Whole Is Much More Than The Sum Of The Parts
- 08/25/2021
|
BioLife Solutions' (BLFS) CEO Mike Rice on Q2 2021 Results - Earnings Call Transcript
- BioLife Solutions' (BLFS) CEO Mike Rice on Q2 2021 Results - Earnings Call Transcript
- 08/12/2021
|
BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Top Estimates
- BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 480.00% and 10.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/12/2021
|
Recap: BioLife Solutions Q2 Earnings
- Shares of BioLife Solutions (NASDAQ:BLFS) moved higher by 4.2% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to ($0.00), which beat the estimate of ($0.07).
- 08/12/2021
|
Sexton Biotechnologies to be Acquired by Biolife Solutions
- INDIANAPOLIS, Aug. 9, 2021 /PRNewswire/ -- Sexton Biotechnologies, a provider of novel manufacturing solutions for the cell and gene therapy (CGT) industry, today announced that it has entered into a definitive agreement whereby BioLife Solutions (NASDAQ: BLFS) will acquire all outstanding shares of the company in a deal worth a total value of $30 million. During the past two years, Sexton has worked to provide end-to-end solutions for emerging cell and gene therapy manufacturers.
- 08/09/2021
|
BioLife Solutions, Inc. (BLFS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
- BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2021
|
BioLife Solutions: Cryobiology Specialist, Aggressive M&A-Led Triple-Digit-Growth Ahead
- BioLife Solutions, Inc. is a developer, manufacturer, and marketer of bioproduction tools and services for the cell and gene therapy industry.
- 06/21/2021
|
BioLife Solutions: Profiting From A Powerful Industry Tailwind
- BioLife Solutions: Profiting From A Powerful Industry Tailwind
- 06/21/2021
|
BioLife Solutions Adopts New Brand Identity
- BOTHELL, Wash., June 15, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the launch of its new corporate brand identity, redesigned logo, and website.
- 06/15/2021
|
BioLife Solutions Announces Promotion of Caitlin Rice to Global Vice President, Customer Service
- BOTHELL, Wash., May 19, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced the promotion of Caitlin Rice to the leadership position of Global Vice President, Customer Service, reporting to Dusty Tenney, President and Chief Operating Officer.
- 05/19/2021
|
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2021 Results - Earnings Call Transcript
- BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2021 Results - Earnings Call Transcript
- 05/13/2021
|
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates
- BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 40.00% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2021
|
Earnings Preview: BioLife Solutions, Inc. (BLFS) Q1 Earnings Expected to Decline
- BioLife Solutions, Inc. (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/06/2021
|
BioLife Solutions Announces Closing of Stirling Ultracold Acquisition and Expanded Partnership with Leading Global Biopharma CDMO
- BOTHELL, Wash., May 3, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed the previously announced acquisition of Stirling Ultracold ("Stirling"), a privately held manufacturer of ultra-low temperature ("ULT") mechanical freezers.
- 05/03/2021
|
BioLife Solutions Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer
- BOTHELL, Wash., April 15, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has launched a new line of high capacity controlled rate freezers (HCRF), with an initial shipment to a leading cell therapy company.
- 04/15/2021
|
HRC or BLFS: Which Is the Better Value Stock Right Now?
- HRC vs. BLFS: Which Stock Is the Better Value Option?
- 04/09/2021
|
BioLife Solutions Appoints Two New Independent Board Directors
- BOTHELL, Wash., April 6, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced that it has appointed Amy DuRoss, chief executive officer of Vineti, and Rachel Ellingson, senior vice president and chief strategy officer at Zimmer Biomet to its board of directors effective immediately.
- 04/06/2021
|
BLFS Stock Price Increases Over 15% Pre-Market: Why It Happened
- The stock price of BioLife Solutions Inc (NASDAQ: BLFS) increased by over 15% pre-market. This is why it happened.
- 03/23/2021
|
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2020 Results - Earnings Call Transcript
- BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q4 2020 Results - Earnings Call Transcript
- 03/22/2021
|
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
- BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 0.00% and 9.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/22/2021
|
BioLife Solutions: Q4 Earnings Insights
- Shares of BioLife Solutions (NASDAQ:BLFS) rose 9.7% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 0.00% year over year to ($0.01), which beat the estimate of ($0.02).
- 03/22/2021
|
Stirling Ultracold to Merge with BioLife Solutions, the Leader in Gene and Cell Therapy Bioproduction Tools and Services
- COLUMBUS, Ohio, March 22, 2021 /PRNewswire/ -- Stirling Ultracold, an Ohio-based manufacturer and provider of the most energy efficient, sustainable ultra-low temperature (ULT) biorepositories has entered into a definitive agreement to merge with BioLife Solutions (NASDAQ: BLFS), a leading provider of bioproduction products and services for the Gene and Cell Therapy (GCT) markets. Stirling Ultracold is backed by the Ohio Innovation Fund (OIF), with OIF Managing Director Bill Baumel serving on the board, the Strategic Committee alongside CEO Dusty Tenney, and acting as the Seller Representative in this transaction -- OIF Principal Faith Voinovich led the reverse diligence on BioLife for Stirling.
- 03/22/2021
|
BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results
- BOTHELL, Wash., March 22, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results for the fourth quarter and year ended December 31, 2020.
- 03/22/2021
|
BioLife Solutions to Acquire Stirling Ultracold in an All-Stock Merger
- BOTHELL, Wash., March 22, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a definitive merger agreement to acquire Global Cooling, Inc., operating as Stirling Ultracold ("Stirling"), a privately held manufacturer of ultra-low temperature ("ULT") mechanical freezers.
- 03/22/2021
|
HRC vs. BLFS: Which Stock Is the Better Value Option?
- HRC vs. BLFS: Which Stock Is the Better Value Option?
- 03/08/2021
|
Analysts Back a Turnaround at BioLife Solutions
- BioLife Solutions shares opened higher before moving sharply lower Thursday despite a higher analyst price target.
- 02/27/2021
|
HRC vs. BLFS: Which Stock Should Value Investors Buy Now?
- HRC vs. BLFS: Which Stock Is the Better Value Option?
- 02/18/2021
|
3 Soaring MedTech Stocks That Might Lose Ground in 2021
- Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.
- 12/30/2020
|
BioLife Solutions, Inc.'s (BLFS) CEO Michael Rice on Q3 2020 Results - Earnings Call Transcript
- BioLife Solutions, Inc.'s (BLFS) CEO Michael Rice on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioLife Solutions
- 08/08/2020
|
Oppenheimer Believes BioLife Solutions (NASDAQ: BLFS) Won't Stop Here - Markets
- Oppenheimer analyst Suraj Kalia maintained a Buy rating on BioLife Solutions (BLFS – Research Report) yesterday and set a price
- 08/07/2020
|
BioLife Solutions Announces Second Quarter 2020 Financial Results
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three and six months ended June 30, 2020.
- 08/06/2020
|
Should You Buy BioLife (BLFS) Ahead of Earnings?
- BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/05/2020
|
When Should You Buy BioLife Solutions, Inc. (NASDAQ:BLFS)?
- While BioLife Solutions, Inc. (NASDAQ:BLFS) might not be the most widely known stock at the moment, it received a lot...
- 08/03/2020
|
BioLife Solutions to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced that the Company's second quarter 2020 financial results will be released after market close on Thursday, August 6th, 2020, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
- 07/30/2020
|
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
ABIOMED, Inc. (NASDAQ: ABMD)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
Bio-Rad Laboratories,...
- 07/23/2020
|
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 21)
ABIOMED, Inc. (NASDAQ: ABMD)
Assembly Biosciences Inc (NASDAQ: ASMB)
Bio-Rad Laboratories, Inc. (NYSE: BIO)...
- 07/22/2020
|
BioLife Solutions (NASDAQ:BLFS) Stock Rating Upgraded by BidaskClub
- BidaskClub upgraded shares of BioLife Solutions (NASDAQ:BLFS) from a hold rating to a buy rating in a research note released on Wednesday morning, BidAskClub reports. Other equities analysts also recently issued research reports about the stock. Maxim Group upped their price objective on shares of BioLife Solutions from $18.00 to $26.00 and gave the company […]
- 07/19/2020
|
BioLife Solutions evo® Cold Chain Management Platform Now Supporting Over 100 Early Stage Cell & Gene Therapy Clinical Trials
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today provided an update on adoption of its evo cold chain management platform solution by cell and gene therapy companies.
- 07/15/2020
|
Week 29 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
- Two new sample MDA Breakout Stocks for Week 29 with better than 10% short-term upside potential and now up an average 152.47% YTD.
- 07/12/2020
|
BioLife Solutions Announces Closing of $86 Million Public Offering of Common Stock
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price of $14.50 per share, which includes the shares purchased pursuant to the exercise in full of the underwriters' option to purchase up to an additional 776,250 shares of its common stock. The gross proceeds from the offering to BioLife, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $86 million.
- 07/07/2020
|
Moving Average Crossover Alert: BioLife Solutions
- BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- 07/06/2020
|
BioLife (BLFS) Catches Eye: Stock Jumps 12.1%
- BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.
- 07/06/2020
|
Analysts Conflicted on These Healthcare Names: Tiziana Life Sciences (NASDAQ: TLSA), BioLife Solutions (NASDAQ: BLFS) and CytoDyn (Other OTC: CYDY) - Markets
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on Tiziana Life Sciences (TLSA –
- 07/06/2020
|
Here's Why BioLife Solutions Jumped Higher Today
- It doesn't look like the COVID-19 pandemic had much effect on sales of the company's bioproduction products for cell and gene therapies.
- 07/02/2020
|
BIOLIFE SOLUTIONS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to BioLife, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75 million. The offering is expected to close on July 7, 2020, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 776,250 shares of common stock from BioLife at the public offering price, less underwriting discounts and commissions.
- 07/02/2020
|
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
AbbVie Inc (NYSE: ABBV)
ADC...
- 07/02/2020
|
BioLife Solutions Announces $9.6 Million to $9.8 Million in Preliminary Revenue for Q2 2020
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced estimated preliminary revenue for the second quarter of 2020 of $9.6 million to $9.8 million, representing 43% to 46% growth over the same quarter in 2019.
- 07/01/2020
|
BioLife Solutions Announces Proposed Public Offering of Common Stock
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, BioLife expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares to be issued and sold in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 07/01/2020
|
Edited Transcript of BLFS.OQ earnings conference call or presentation 14-May-20 8:30pm GMT
- Q1 2020 Biolife Solutions Inc Earnings Call
- 06/26/2020
|
Is BioLife Solutions, Inc. (BLFS) A Good Stock To Buy?
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- 06/26/2020
|
BioLife Solutions Inc (NASDAQ:BLFS) Position Lifted by Wellington Management Group LLP
- Wellington Management Group LLP grew its position in shares of BioLife Solutions Inc (NASDAQ:BLFS) by 82.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 256,400 shares of the medical equipment provider’s stock after buying an additional 116,100 shares during the […]
- 06/26/2020
|
China Cold Chain Logistics Industry Report 2020-2026 Featuring Profiles of 22 Operators Including Xianyi Holdings, ZM Logistics, Shandong Gaishi Int'l Logistics Group, Shenyang Nonstaple Food Group - ResearchAndMarkets.com
|
BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales. He is replacing Jim Mathers, Chief Revenue Officer, who is retiring on June 30, 2020.
- 05/18/2020
|
BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2020 Results - Earnings Call Transcript
- BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Roderick de Greef - Chief Financial Officer
- 05/15/2020
|
Biolife Solutions Inc (BLFS) Q1 2020 Earnings Call Transcript
- Now I'd like to turn the call over to Mike Rice, President and CEO of BioLife. For the last month or so of the quarter, we had our team members either working from home, part of an essential reduced on site workforce who are not working through all the transition to get our customer support teams up and running remotely, we stayed in close contact with our customers and shipped more media products than in any other period and BioLife history. While it's clear that cell and gene therapy clinical trials have been significantly affected by the reallocation of hospital beds to COVID patients, our customers are planning for success and clearly demonstrated through their order volume that our media products are considered mission critical to their cell and gene therapy manufacturing workflow.
- 05/15/2020
|
BioLife Solutions Announces First Quarter 2020 Financial Results
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three months ended March 31, 2020.
- 05/14/2020
|
Global Organ Transplant Market Review 2015-2019 and Forecast to 2025 (Impact of COVID-19) - ResearchAndMarkets.com
|
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
- On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.
- 05/13/2020
|
Why Earnings Season Could Be Great for BioLife Solutions (BLFS)
- BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/13/2020
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
- 05/13/2020
|
What's in the Cards for SmileDirectClub's (SDC) Q1 Earnings?
- Stocks Analysis by Zacks Investment Research covering: CVS Health Corp, BioLife Solutions Inc, Hexo Corp, SmileDirectClub Inc. Read Zacks Investment Research's latest article on Investing.com
- 05/12/2020
|
BioLife Solutions to Report First Quarter 2020 Financial Results and Provide Business Update on May 14th, 2020
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that the Company's first quarter 2020 financial results will be released after market close on Thursday, May 14th, 2020, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.
- 05/11/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
Analysts' Top Healthcare Picks: Lemaitre Vascular (LMAT), Aerie Pharma (AERI)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lemaitre Vascular (LMAT), Aerie Pharma (AERI) and BioLife
- 05/01/2020
|
Analysts’ Top Healthcare Picks: Lemaitre Vascular (LMAT), Aerie Pharma (AERI)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lemaitre Vascular (
LMAT
–
Research Report
), Aerie Pharma (
AERI
–
Research Report
) and BioLife Solutions (
BLFS
–
Research Report
) with bullish sentime
- 05/01/2020
|
BioLife Solutions Announces Preliminary First Quarter 2020 Revenue
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced preliminary revenue for the first quarter of 2020.
- 05/01/2020
|
Stocks To Watch: Tech Powerhouses Lead Earnings Blitz
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 04/25/2020
|
Bank of New York Mellon Corp Increases Stock Position in BioLife Solutions Inc (NASDAQ:BLFS)
- Bank of New York Mellon Corp lifted its holdings in BioLife Solutions Inc (NASDAQ:BLFS) by 15.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 90,676 shares of the medical equipment provider’s stock after purchasing an additional 12,198 shares during the period. Bank of New York Mellon Corp’s […]
- 04/24/2020
|
Is BioLife Solutions, Inc. (NASDAQ:BLFS) A Volatile Stock?
- Anyone researching BioLife Solutions, Inc. (NASDAQ:BLFS) might want to consider the historical volatility of the share...
- 04/20/2020
|
Insider Selling: BioLife Solutions Inc (NASDAQ:BLFS) CEO Sells $169,312.50 in Stock
- BioLife Solutions Inc (NASDAQ:BLFS) CEO Michael Rice sold 18,750 shares of BioLife Solutions stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $9.03, for a total transaction of $169,312.50. Following the sale, the chief executive officer now owns 233,489 shares in the company, valued at […]
- 04/18/2020
|
$9.59 Million in Sales Expected for BioLife Solutions Inc (NASDAQ:BLFS) This Quarter
- Wall Street analysts expect that BioLife Solutions Inc (NASDAQ:BLFS) will post sales of $9.59 million for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for BioLife Solutions’ earnings, with estimates ranging from $8.50 million to $11.10 million. BioLife Solutions reported sales of $5.77 million during the same quarter last year, […]
- 04/17/2020
|
Franklin Resources Inc. Acquires Shares of 24,610 BioLife Solutions Inc (NASDAQ:BLFS)
- Franklin Resources Inc. acquired a new stake in BioLife Solutions Inc (NASDAQ:BLFS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 24,610 shares of the medical equipment provider’s stock, valued at approximately $398,000. Franklin Resources Inc. owned about 0.12% of BioLife Solutions at the end […]
- 04/14/2020
|
Edited Transcript of BLFS earnings conference call or presentation 11-Mar-20 8:30pm GMT
- Q4 2019 Biolife Solutions Inc Earnings Call
- 03/30/2020
|
How Does BioLife Solutions's (NASDAQ:BLFS) P/E Compare To Its Industry, After The Share Price Drop?
- Unfortunately for some shareholders, the BioLife Solutions (NASDAQ:BLFS) share price has dived 36% in the last thirty...
- 03/28/2020
|
BioLife Solutions (BLFS) Received its Third Buy in a Row
- After B.Riley FBR and Oppenheimer gave BioLife Solutions (NASDAQ: BLFS) a Buy rating last month, the company received another Buy, this time from H.C.
- 03/23/2020
|
BioLife Solutions (BLFS) Received its Third Buy in a Row
- After B.Riley FBR and Oppenheimer gave BioLife Solutions (NASDAQ: BLFS) a Buy rating last month, the company received another Buy,
- 03/23/2020
|
Did You Miss BioLife Solutions's (NASDAQ:BLFS) Whopping 428% Share Price Gain?
- Some BioLife Solutions, Inc. (NASDAQ:BLFS) shareholders are probably rather concerned to see the share price fall 42...
- 03/14/2020
|
Stocks To Watch: 0% To The Rescue?
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 03/14/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
BioLife Solutions (BLFS) Received its Third Buy in a Row
- After Benchmark Co. and B.Riley FBR gave BioLife Solutions (NASDAQ: BLFS) a Buy rating last month, the company received another Buy, this time from
- 03/12/2020
|
BioLife Solutions (BLFS) Received its Third Buy in a Row
- After Benchmark Co. and B.Riley FBR gave BioLife Solutions (NASDAQ: BLFS) a Buy rating last month, the company received another
- 03/12/2020
|
BioLife Solutions Announces Fourth Quarter and Full Year 2019 Financial Results
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational highlights for the fourth quarter and full year ended December 31, 2019.
- 03/11/2020
|
BioLife Solutions, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 11, 2020 / BioLife Solutions, Inc. (NASDAQ:BLFS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2020 at 4:30 ...
- 03/11/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV
- 03/11/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Enzo Biochem, Inc. (NYSE: ENZ) * Centogene NV (NASDAQ: CNTG) * Inovio Pharmaceuticals Inc (NASDAQ:
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. View more earnings on IBBThe following are key catalysts in the unfolding week that a biotech
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
Stifel likes Alector and Denali in premarket analyst action
- Alector (NASDAQ:ALEC) initiated with Buy rating and $44 (52% upside) price target at Stifel.Aridis Pharmaceuticals (NASDAQ:ARDS) initiated with Buy rating and $18 (193% upside) price target at Roth Ca
- 02/19/2020
|
What Does BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Indicate?
- BioLife Solutions, Inc. (NASDAQ:BLFS), which is in the medical equipment business, and is based in United States, saw...
- 02/17/2020
|
BioLife Solutions Announces Earnings Call Date and Upcoming Investor and Scientific Conferences
- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the dates for several key events:
- 02/12/2020
|
Analysts Back a Turnaround at BioLife Solutions
- BioLife Solutions shares opened higher before moving sharply lower Thursday despite a higher analyst price target.
- 02/07/2020
|
Mizuho likes AbbVie in premarket analyst action
- AbbVie (NYSE:ABBV) initiated with Buy rating and $96 (11% upside) price target at Mizuho Securities. Shares up a fraction premarket.Alkermes plc (NASDAQ:ALKS) initiated with Neutral rating and $19 (fl
- 02/06/2020
|
The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...
- 02/04/2020
|
Here's Why We Think BioLife Solutions (NASDAQ:BLFS) Is Well Worth Watching
- Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
- 01/22/2020
|
Edited Transcript of BLFS earnings conference call or presentation 12-Nov-19 9:30pm GMT
- Q3 2019 Biolife Solutions Inc Earnings Call
- 01/04/2020
|
How Much Did BioLife Solutions, Inc.'s (NASDAQ:BLFS) CEO Pocket Last Year?
- In 2006 Mike Rice was appointed CEO of BioLife Solutions, Inc. (NASDAQ:BLFS). First, this article will compare CEO...
- 12/30/2019
|
What could you have made by investing $1,000 in these Washington companies a decade ago?
- Of Washington's public companies, 21 at least doubled their stock price from Dec. 27, 2010 to Dec. 26, 2019.
- 12/27/2019
|
